Results 141 to 150 of about 19,705 (163)

Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans

Xenobiotica, 2018
Shiyao Xu
exaly  

DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo

Biomedicine and Pharmacotherapy, 2019
Aseel Marahleh, Hideki Kitaura, Jiawei Qi   +2 more
exaly  

MEDICAL USE OF A DPP-4 INHIBITOR

2015
KLEIN THOMAS, ADVANI ANDREW, CONNELLY KIM ALEXANDER, GILBERT RICHARD ERNEST   +3 more
openaire   +3 more sources

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

Current Medical Research and Opinion, 2008
Pablo Aschner, Avraham Karasik
exaly  

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

European Journal of Pharmacology, 2014
Henrik H Hansen, Jacob Jelsing
exaly  

A case of dropped head syndrome suspected due to Dipeptidyl peptidase (DPP)-4 inhibitor use

Clinical Neurology, 2021
exaly  

Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728

Tetrahedron, 2002
Willand Nicolas, Jürgen Joossens
exaly  

SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, 2018
Tiansheng Wang, Dandan Li, Huilin Tang   +2 more
exaly  

Trough DPP-4 Inhibition Differs between the Approved DPP-4 Inhibitors

MD Conference Express, 2013
openaire   +1 more source

Design and synthesis of DPP-4 inhibitor for the treatment of type 2 diabetes

Chinese Chemical Letters, 2010
exaly